Menu Search
Equities

NeuroMetrix Inc

NURO:NAQ

NeuroMetrix Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.93
  • Today's Change0.11 / 2.88%
  • Shares traded18.36k
  • 1 Year change-28.62%
  • Beta2.2936
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year NeuroMetrix Inc's revenues fell -28.52% from 8.26m to 5.90m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 4.42m to a larger loss of 6.53m.
Gross margin60.19%
Net profit margin-181.03%
Operating margin-203.04%
Return on assets-38.06%
Return on equity-40.99%
Return on investment-40.80%
More ▼

Cash flow in USDView more

In 2023, cash reserves at NeuroMetrix Inc fell by 2.60m. Cash Flow from Financing totalled 2.33m or 39.40% of revenues. In addition the company used 6.08m for operations while cash from investing totalled 1.16m.
Cash flow per share-5.20
Price/Cash flow per share--
Book value per share8.58
Tangible book value per share8.58
More ▼

Balance sheet in USDView more

NeuroMetrix Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio11.62
Quick ratio10.71
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.